Who owns enGene Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ENGN from SEC Form 13F filings across 58 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 58 institutions disclosed 37.8M shares of enGene Therapeutics Inc. worth $75.6M — about 54.2% of shares outstanding; the largest disclosed holder is BML Capital Management, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
58
13F holders
$75.6M
value, 2026 filers
54.2%
of shares outstanding (37.8M sh)
17
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ENGN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 6.7M | $13.3M | 7.1% | 9.6% | 0.0% |
| 2 | Siren, L.L.C. | 6.3M | $12.5M | 0.3% | 9% | 0.0% |
| 3 | ACORN CAPITAL ADVISORS, LLC | 3.8M | $7.6M | 2.1% | 5.5% | +199.8% |
| 4 | PERCEPTIVE ADVISORS LLC | 3.5M | $7.0M | 0.1% | 5% | -27.8% |
| 5 | EVENTIDE ASSET MANAGEMENT, LLCNEW | 3.4M | $6.8M | 0.1% | 4.9% | new |
| 6 | Nextech Invest Ltd. | 2.3M | $4.6M | 0.2% | 3.3% | 0.0% |
| 7 | Vestal Point Capital, LP | 1.7M | $3.3M | 0.1% | 2.4% | -0.1% |
| 8 | ADAR1 Capital Management, LLC | 1.3M | $2.7M | 0.1% | 1.9% | -36.8% |
| 9 | TWO SIGMA INVESTMENTS, LP | 1.3M | $2.6M | 0.0% | 1.9% | +685.2% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1.1M | $2.3M | 0.0% | 1.6% | +36.7% |
| 11 | Peapod Lane Capital LLC | 1.0M | $2.1M | 1.5% | 1.5% | -5.8% |
| 12 | SR ONE CAPITAL MANAGEMENT, LPNEW | 747,750 | $1.5M | 0.1% | 1.1% | new |
| 13 | Aldebaran Capital, LLCNEW | 657,319 | $1.3M | 0.9% | 0.9% | new |
| 14 | FLPUTNAM INVESTMENT MANAGEMENT CONEW | 556,121 | $1.1M | 0.0% | 0.8% | new |
| 15 | Kynam Capital Management, LP | 457,855 | $915,710 | 0.1% | 0.7% | 0.0% |
| 16 | CITADEL ADVISORS LLC | 444,471 | $888,942 | 0.0% | 0.6% | -38.1% |
| 17 | Squarepoint Ops LLC | 299,747 | $599,494 | 0.0% | 0.4% | +39.2% |
| 18 | JANE STREET GROUP, LLC | 291,730 | $583,460 | 0.0% | 0.4% | -23.7% |
| 19 | Rangeley Capital, LLC | 287,898 | $575,796 | 0.8% | 0.4% | -5.6% |
| 20 | MILLENNIUM MANAGEMENT LLC | 181,619 | $363,238 | 0.0% | 0.3% | -81.2% |
| 21 | D. E. Shaw & Co., Inc.NEW | 170,408 | $340,816 | 0.0% | 0.2% | new |
| 22 | Privium Fund Management B.V. | 170,000 | $340,000 | 0.1% | 0.2% | 0.0% |
| 23 | GSA CAPITAL PARTNERS LLP | 127,975 | $256,000 | 0.0% | 0.2% | +242.7% |
| 24 | XTX Topco Ltd | 117,582 | $235,164 | 0.0% | 0.2% | -22.3% |
| 25 | Quadrature Capital Ltd | 100,069 | $200,138 | 0.0% | 0.1% | -58.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.